pertuzumab

{
  "id": "MLC-T-ONC-006552",
  "term": "pertuzumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with other drugs to treat breast cancer that is HER2 positive. It is used in patients whose cancer has spread to other parts of the body and has not already been treated with other anticancer drugs. It is also used before surgery in patients with locally advanced, inflammatory, or early-stage breast cancer and after surgery in patients with early-stage breast cancer who have a high risk that their cancer will recur (come back). It is also being studied in the treatment of other types of cancer. Pertuzumab binds to a protein called HER2, which is found on some cancer cells. Blocking this protein may help kill cancer cells. Pertuzumab is a type of monoclonal antibody. Also called Perjeta.",
    "A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis."
  ],
  "abbreviation": "MOAB 2C4",
  "synonyms": [
    "Perjeta",
    "rhuMAb-2C4",
    "2C4 antibody",
    "monoclonal antibody 2C4",
    "rhuMAb2C4",
    "2C4",
    "pertuzumab biosimilar HS627",
    "pertuzumab biosimilar HLX11",
    "pertuzumab biosimilar EG1206A",
    "pertuzumab biosimilar TQB2440",
    "omnitarg",
    "pertuzumab biosimilar BCD-178"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pertuzumab/"
}